Dimensional Fund Advisors LP Increases Holdings in Lantern Pharma Inc. (NASDAQ:LTRN)

Dimensional Fund Advisors LP increased its holdings in shares of Lantern Pharma Inc. (NASDAQ:LTRN) by 55.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,413 shares of the company’s stock after purchasing an additional 6,585 shares during the period. Dimensional Fund Advisors LP owned 0.17% of Lantern Pharma worth $86,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in LTRN. Westside Investment Management Inc. acquired a new position in Lantern Pharma in the 2nd quarter worth $54,000. Tocqueville Asset Management L.P. acquired a new stake in shares of Lantern Pharma in the 1st quarter valued at about $167,000. Finally, CM Management LLC raised its stake in shares of Lantern Pharma by 23.1% in the 2nd quarter. CM Management LLC now owns 80,000 shares of the company’s stock valued at $374,000 after purchasing an additional 15,000 shares in the last quarter. 28.62% of the stock is owned by hedge funds and other institutional investors.

Lantern Pharma Stock Performance

Shares of Lantern Pharma stock opened at $3.54 on Wednesday. The firm has a market cap of $38.09 million, a PE ratio of -2.17 and a beta of 1.55. The firm’s 50-day simple moving average is $3.90 and its 200-day simple moving average is $4.94. Lantern Pharma Inc. has a 1 year low of $2.38 and a 1 year high of $11.99.

Lantern Pharma (NASDAQ:LTRN) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.09. During the same quarter last year, the business posted ($0.44) EPS. On average, equities analysts predict that Lantern Pharma Inc. will post -2.12 earnings per share for the current year.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.